MOUNJARO® 7.5mg KwikPen®, 1 Stk.

Description

Name: MOUNJARO® 7.5mg KwikPen®, 1 Stk.
Manufacturer: Eli Lilly and Company Limited
Active Substance(s): TIRZEPATIDE
Strength: 7.5mg/0.6ml injection
Package Content: 1 box with 4 pre-filled KwikPens

MOUNJARO® 7.5mg KwikPen® is a multi-dose pre-filled injection device designed to deliver a fixed dose of 7.5 mg tirzepatide in 0.6 mL once weekly. It is indicated for the treatment of adults with type 2 diabetes mellitus and for weight management in patients with obesity or overweight conditions linked to health risks. Each KwikPen® contains 2.4 mL solution with a total of 30 mg tirzepatide, providing four weekly doses. The formulation is a clear, colourless to slightly yellow liquid and is administered by subcutaneous injection into the abdomen, thigh, or upper arm.

• Provides 4 doses of 7.5 mg each (0.6 mL per injection)

• Once-weekly administration supports adherence and convenience

• Used as a titration step before reaching higher maintenance doses

MOUNJARO® 7.5mg KwikPen® is provided in a KwikPen® device containing 2.4 mL solution, sufficient for four doses. Packs may include either a single pen or a set of three pens, with pen needles not included and requiring separate purchase.

The solution contains tirzepatide as the active pharmaceutical ingredient, along with carefully selected excipients to maintain stability and sterility.

• Active substance: Tirzepatide 7.5 mg per 0.6 mL injection

• Total pen content: 30 mg tirzepatide in 2.4 mL (12.5 mg/mL concentration)

• Excipients: Disodium hydrogen phosphate heptahydrate, benzyl alcohol (~5.4 mg per dose), glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, and water for injections

• Sodium content: Less than 1 mmol (23 mg) sodium per dose, essentially sodium-free

• Appearance: Clear, colourless to slightly yellow solution

MOUNJARO® 7.5mg is used in the treatment of type 2 diabetes mellitus in adults who require improved glycaemic control, either as monotherapy or in combination with other antidiabetic medicines. It is also indicated for weight management, including weight reduction and maintenance, in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² if they have weight-related conditions such as hypertension, cardiovascular disease, dyslipidaemia, obstructive sleep apnoea, or prediabetes.

• Indications:

  • Management of type 2 diabetes mellitus

  • Weight loss and maintenance in adults with BMI ≥30 kg/m²

  • Overweight patients (BMI ≥27 kg/m²) with comorbidities

• Contraindications:

  • Known hypersensitivity to tirzepatide or excipients

  • Not recommended in severe gastrointestinal diseases (e.g., gastroparesis)

  • Use with caution in patients with a history of pancreatitis

• Side effects:

  • Very common: Nausea, vomiting, diarrhoea, abdominal pain, constipation

  • Common: Loss of appetite, dyspepsia, dizziness, fatigue, mild injection-site reactions

  • Occasional: Gallbladder events such as gallstones or cholecystitis

  • Rare: Acute pancreatitis, serious allergic reactions (e.g., angioedema, anaphylaxis)

  • Laboratory changes: Elevated amylase and lipase levels

MOUNJARO® 7.5mg is injected once weekly at a consistent time, with or without meals. The dose should be administered into the abdomen, thigh, or upper arm, and injection sites should be rotated with each dose to prevent irritation. Patients can self-administer following proper training.

• Dosing protocol:

  • Start at 2.5 mg weekly for 4 weeks, then gradually escalate

  • 7.5 mg serves as an intermediate titration dose before higher levels

  • Maximum dose: 15 mg once weekly

• Missed dose instructions:

  • If ≤4 days late: inject as soon as possible

  • If >4 days late: skip and continue with the next scheduled dose

• Injection method:

  • Always attach a new sterile needle before use

  • Dial to 1 in the dose window (=0.6 mL dose)

  • Inject subcutaneously, hold for 5 seconds until window shows 0

  • Remove and discard the needle in a sharps container

Correct storage is critical to preserve product safety and effectiveness.

• Unopened pens: Store refrigerated at 2–8 °C

• Do not freeze; discard if frozen

• After first use: May be stored at ≤30 °C for up to 30 days

• Discard after 30 days, even if liquid remains

• Keep out of reach of children

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.